Jack Stewart, CSO of Soricimed Biopharma discusses SOR-C13, a selective inhibitor of TRPV6, binds with affinity and disrupts how TRPV6 functions.
Jack Stewart, CSO of Soricimed Biopharma discusses SOR-C13, a selective inhibitor of TRPV6, binds with affinity and disrupts how TRPV6 functions.